MX351288B - Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. - Google Patents
Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta.Info
- Publication number
- MX351288B MX351288B MX2014009298A MX2014009298A MX351288B MX 351288 B MX351288 B MX 351288B MX 2014009298 A MX2014009298 A MX 2014009298A MX 2014009298 A MX2014009298 A MX 2014009298A MX 351288 B MX351288 B MX 351288B
- Authority
- MX
- Mexico
- Prior art keywords
- indazole
- disorders
- glycogen synthase
- synthase kinase
- carboxamide compounds
- Prior art date
Links
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 title abstract 4
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 title abstract 4
- 150000008581 1H-indazole-3-carboxamides Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12156298 | 2012-02-21 | ||
| PCT/EP2013/052523 WO2013124169A1 (en) | 2012-02-21 | 2013-02-08 | Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009298A MX2014009298A (es) | 2014-10-14 |
| MX351288B true MX351288B (es) | 2017-10-09 |
Family
ID=47710141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009298A MX351288B (es) | 2012-02-21 | 2013-02-08 | Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9163013B2 (https=) |
| EP (1) | EP2817301B1 (https=) |
| JP (1) | JP6285873B2 (https=) |
| KR (1) | KR102101702B1 (https=) |
| CN (1) | CN104080781B (https=) |
| AR (1) | AR090085A1 (https=) |
| AU (1) | AU2013224313B2 (https=) |
| BR (1) | BR112014018657B1 (https=) |
| CA (1) | CA2860466C (https=) |
| CY (1) | CY1117467T1 (https=) |
| DK (1) | DK2817301T3 (https=) |
| EA (1) | EA026952B1 (https=) |
| ES (1) | ES2564033T3 (https=) |
| GE (1) | GEP201606552B (https=) |
| HR (1) | HRP20160124T1 (https=) |
| HU (1) | HUE027445T2 (https=) |
| IL (1) | IL233825A (https=) |
| MX (1) | MX351288B (https=) |
| PL (1) | PL2817301T3 (https=) |
| PT (1) | PT2817301E (https=) |
| RS (1) | RS54539B1 (https=) |
| SG (2) | SG11201403788VA (https=) |
| SI (1) | SI2817301T1 (https=) |
| SM (1) | SMT201600054B (https=) |
| UA (1) | UA113189C2 (https=) |
| WO (1) | WO2013124169A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS54539B1 (sr) * | 2012-02-21 | 2016-06-30 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze |
| WO2016036586A1 (en) * | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| KR20180011843A (ko) | 2015-06-11 | 2018-02-02 | 바실리어 파마슈티카 인터내셔널 리미티드 | 유출-펌프 억제제 및 이의 치료적 용도 |
| WO2017093157A1 (en) * | 2015-11-30 | 2017-06-08 | Basilea Pharmaceutica Ag | Piperidine, pyrrolidine and 2-oxo-1,3-oxazinane derivatives as inhibitors of bacterial efflux-pumps for the treatment of microbial infections |
| US20190298705A1 (en) * | 2016-06-08 | 2019-10-03 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| PT3790873T (pt) * | 2018-05-07 | 2022-05-11 | Acraf | Compostos de 1h-indazole-3-carboxamida como inibidores da glicogénio sintase cinase 3 beta |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| KR102906523B1 (ko) | 2018-09-13 | 2025-12-30 | 브리스톨-마이어스 스큅 컴퍼니 | 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 |
| CN117186027B (zh) * | 2023-09-11 | 2024-04-19 | 上海蓝木化工有限公司 | 一种糖原合酶激酶-3抑制剂及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ257545A (en) | 1992-11-05 | 1997-01-29 | Smithkline Beecham Plc | Heterocyclic (especially piperidine) derivatives and pharmaceutical compositions |
| EP0829474B1 (en) * | 1995-05-31 | 2003-04-09 | Nisshin Seifun Group Inc. | Indazole derivatives having monocyclic amino group |
| IT1291569B1 (it) * | 1997-04-15 | 1999-01-11 | Angelini Ricerche Spa | Indazolammidi come agenti serotoninergici |
| GB0218625D0 (en) | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| ITMI20030287A1 (it) * | 2003-02-18 | 2004-08-19 | Acraf | Indazolammidi dotate di attivita' analgesica metodo, per |
| ITMI20030972A1 (it) * | 2003-05-15 | 2004-11-16 | Acraf | Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende. |
| UA99927C2 (uk) | 2007-11-12 | 2012-10-25 | Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. | Медикамент, який є активним при невропатичному болі |
| TW201040191A (en) | 2009-03-27 | 2010-11-16 | Abbott Gmbh & Co Kg | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US7947728B1 (en) * | 2009-11-11 | 2011-05-24 | Hoffmann-La Roche Inc. | Indole and indazole analogs as glycogen synthase activators |
| CA2860250C (en) * | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| RS54539B1 (sr) * | 2012-02-21 | 2016-06-30 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze |
-
2013
- 2013-02-08 RS RS20160091A patent/RS54539B1/sr unknown
- 2013-02-08 EP EP13703799.0A patent/EP2817301B1/en active Active
- 2013-02-08 DK DK13703799.0T patent/DK2817301T3/en active
- 2013-02-08 HR HRP20160124TT patent/HRP20160124T1/hr unknown
- 2013-02-08 SI SI201330133T patent/SI2817301T1/sl unknown
- 2013-02-08 SG SG11201403788VA patent/SG11201403788VA/en unknown
- 2013-02-08 KR KR1020147022709A patent/KR102101702B1/ko not_active Expired - Fee Related
- 2013-02-08 PT PT137037990T patent/PT2817301E/pt unknown
- 2013-02-08 MX MX2014009298A patent/MX351288B/es active IP Right Grant
- 2013-02-08 JP JP2014556994A patent/JP6285873B2/ja active Active
- 2013-02-08 CA CA2860466A patent/CA2860466C/en active Active
- 2013-02-08 AU AU2013224313A patent/AU2013224313B2/en not_active Ceased
- 2013-02-08 US US14/373,393 patent/US9163013B2/en active Active
- 2013-02-08 EA EA201491448A patent/EA026952B1/ru unknown
- 2013-02-08 ES ES13703799.0T patent/ES2564033T3/es active Active
- 2013-02-08 BR BR112014018657-0A patent/BR112014018657B1/pt not_active IP Right Cessation
- 2013-02-08 HU HUE13703799A patent/HUE027445T2/en unknown
- 2013-02-08 PL PL13703799T patent/PL2817301T3/pl unknown
- 2013-02-08 WO PCT/EP2013/052523 patent/WO2013124169A1/en not_active Ceased
- 2013-02-08 SG SG10201701171TA patent/SG10201701171TA/en unknown
- 2013-02-08 CN CN201380007410.2A patent/CN104080781B/zh not_active Expired - Fee Related
- 2013-02-08 GE GEAP201313572A patent/GEP201606552B/en unknown
- 2013-02-19 AR ARP130100501A patent/AR090085A1/es unknown
- 2013-08-02 UA UAA201407125A patent/UA113189C2/uk unknown
-
2014
- 2014-07-27 IL IL233825A patent/IL233825A/en active IP Right Grant
-
2015
- 2015-08-13 US US14/825,261 patent/US9700551B2/en active Active
-
2016
- 2016-02-23 SM SM201600054T patent/SMT201600054B/xx unknown
- 2016-03-15 CY CY20161100218T patent/CY1117467T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX351287B (es) | Compuestos de 1h-indazol-3-carboxamida como inhibidores de glucogeno sintasa quinasa 3 beta. | |
| MX351288B (es) | Uso de compuestos de 1h-indazol-3-carboxamida como beta inhibidores de glucogeno sintasa quinasa 3 beta. | |
| PH12015500963A1 (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
| MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
| PH12014500351B1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| PH12013500299B1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| MY189427A (en) | Pyrazolyl quinoxaline kinase inhibitors | |
| MX2015007921A (es) | Compuestos heterociclicos novedosos como inhibidores de bromodominio. | |
| TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
| MX2014013090A (es) | Derivados de pirrolotriazinona. | |
| WO2012170827A3 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| PH12014500536A1 (en) | Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors | |
| MX2016001536A (es) | Derivados de urea de piperidinas. | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| MX369393B (es) | Derivados de ftalazina. | |
| MX369389B (es) | Apoaecuorina para usarse en aliviar un síntoma asociado con esclerosis múltiple en un sujeto. | |
| MY159995A (en) | Pyrimidinyl indole compounds | |
| NZ744952A (en) | Methods for alleviating symptoms of multiple sclerosis based on apoaequorin-containing compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |